Interval cytoreduction in ovarian cancer
Neijt, J.P.
New England Journal of Medicine 333(4): 254-255; Author Reply 255
1995
ISSN/ISBN: 0028-4793 PMID: 7791844 Document Number: 439819
Document emailed within 1 workday
Related Documents
Gasowska-Bodnar, A.; Bodnar, L.; Wcisło, G.B.; Jerzak, M.łg.M.; Szczylik, C.; Baranowski, W.ło. 2008: CA 125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction Ginekologia Polska 79(2): 108-114Zanaboni, F.; Heintz, A.P.; Trimbos, J.B.; van Lindert, A.C.; Aalders, J.G.; Neijt, J.P. 1988: The role of cytoreduction in ovarian cancer European Journal of Gynaecological Oncology 9(2): 149-152
Fukuyama, A.; Yokoyama, Y.; Wada, J.; Hashimoto, T.; Oda, T.; Sato, S.; Mizunuma, H. 2009: Two cases of ovarian cancer at an early stage incidentally detected using transvaginal ultrasonography in screening: importance of interval for ovarian cancer screening and selection of population with a high risk of ovarian cancer European Journal of Gynaecological Oncology 30(2): 208-210
Robella, M.; Vaira, M.; Marsanic, P.; Mellano, A.; Borsano, A.; Cinquegrana, A.; Sottile, A.; De Simone, M. 2014: Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) Minerva Chirurgica 69(1): 27-35
Spiliotis, J.; Iavazzo, C.; Sugarbaker, P. 2021: Management of patients with advanced ovarian cancer - Role of complete cytoreduction and HIPEC: Attitudes of gynaecologist oncologists in two different continents Australian and New Zealand Journal of Obstetrics and Gynaecology 61(1): E1-E2
Donato, M.L.; Champlin, R.E.; Wharton, J.T.; Bodurka-Bevers, D.; Gershenson, D. 2000: Intensive-dose ifosfamide and etoposide with filgrastim for cytoreduction before peripheral blood stem cell collection in patients with advanced ovarian cancer European Journal of Gynaecological Oncology 21(3): 241-244
Mu, T.; Li, X.-p.; Wang, J.-l.; Wang, S.-j.; Wang, Y.; Sun, X.-l.; Cui, H.; Wei, L.-h. 2012: Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer Zhonghua Fu Chan Ke Za Zhi 47(8): 566-570
Boente, M.P.; Chi, D.S.; Hoskins, W.J. 1998: The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery Seminars in Oncology 25(3): 326-334
Hartge, P.; Hayes, R.; Reding, D.; Sherman, M.E.; Prorok, P.; Schiffman, M.; Buys, S. 2000: Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors: preliminary data from the prostate, lung, colon, and ovarian cancer screening trial American Journal of Obstetrics and Gynecology 183(5): 1232-1237
Suzuki, M.; Sekiguchi, I.; Tamada, T.; Sakurabayashi, I.; Kawai, T. 1985: Clinical evaluation of a cancer antigen CA125 associated with ovarian cancer. (III) Serum CA125 levels in patients with ovarian cancer and other gynecological tumors Rinsho Byori. Japanese Journal of Clinical Pathology 33(2): 173-177
Rose, P.G.; Hunter, R.E. 1994: Advanced ovarian cancer in a woman with a family history of ovarian cancer, discovered at referral for prophylactic oophorectomy. A case report Journal of Reproductive Medicine 39(11): 908-910
Tanaka, K. 1989: Ovarian cancer--assessment of methods for cytogenetic analysis and chromosome aberrations found in ovarian cancer Rinsho Byori. Japanese Journal of Clinical Pathology Spec no 80: 268-280
Du Bois, A.; Lück, H.J.; Meier, W.; Möbus, V.; Costa, S.; Richter, B.; Warm, M.; Bauknecht, T.; Schröder, W.; Olbricht, S.; Nitz, U.; Jackisch, C. 1997: Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase IIi trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group Seminars in Oncology 24(5 Suppl 15: S15
Chou, Y-Ching.; Chen, Y-Jen.; Lai, C-Ru.; Wang, P-Hui.; Hsin-Chan; Yuan, C-Chung. 2006: Cyclooxygenase-2 expression is higher in ovarian cancer tissue adjacent to endometriosis than in ovarian cancer without comorbid endometriosis European Journal of Obstetrics Gynecology and Reproductive Biology 124(1): 101-105
Ivanov, S.; Batashki, I. 2008: Five years survival in patients with endometrioid ovarian cancer versus patients with serous ovarian cancer Akusherstvo i Ginekologiia 47(5): 9-11
Murakami, F.; Kiyozuka, Y.; Nishimura, H.; Imamura, K.; Yakushiji, M.; Noda, T.; Adachi, S.; Ito, K.; Tamori, N.; Shintani, M. 1993: Etoposide/cis-platinum (CDDP) combined chemotherapy for ovarian cancer: evaluation of optimum schedule for CDDP administration in chronic continuous exposure of ovarian cancer cells to low-dose etoposide in vitro Nihon Sanka Fujinka Gakkai Zasshi 45(2): 125-132
Milsom, I.; Odlind, V. 2008: Oral contraceptives give long-lasting protection against ovarian cancer. use of oral contraceptives can explain reduced incidence of ovarian cancer in Sweden Lakartidningen 105(10): 715-716
Ishii, K.; Aoki, Y.; Takakuwa, K.; Tanaka, K. 2001: Ovarian function after radical hysterectomy with ovarian preservation for cervical cancer Journal of Reproductive Medicine 46(4): 347-352
Rohde, E.; Reincke, I.; Barten, M. 1986: Ovarian metastasis of cancer of the small intestine with simultaneous ovarian pregnancy Zentralblatt für Gynakologie 108(19): 1184-1188
Jin, Z.; Gu, J.; Xin, X.; Li, Y.; Wang, H. 2014: Expression of hexokinase 2 in epithelial ovarian tumors and its clinical significance in serous ovarian cancer European Journal of Gynaecological Oncology 35(5): 519-524